Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 3/20 | 0.44 |
| ▸ | CCNK | O75909 | 3/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 12/20 | 0.44 |
| ▸ | JAK1 | P23458 | 11/20 | 0.44 |
| ▸ | JAK3 | P52333 | 11/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358965 | 1.00 | CDK2 (0.47) | CDK2CCNE1CDK1CCNKCDK12 | |
| SCHEMBL4417942 | 0.98 | CDK2 (0.50) | CDK2CCNE1CDK1CCNKCDK12 | |
| SCHEMBL2357909 | 0.98 | CDK2 (0.50) | CDK2CCNE1CDK1CCNKCDK12 | |
| SCHEMBL3709533 | 0.96 | JAK2 (0.45) | CDK2CCNE1CDK1CCNKCDK12 | |
| SCHEMBL3313952 | 0.96 | CDK2 (0.48) | CDK2CCNE1CDK1CCNKCDK12 | |
| SCHEMBL2355841 | 0.94 | CDK2 (0.51) | CDK2CCNE1CDK1CCNKCDK12 | |
| SCHEMBL3712190 | 0.92 | JAK2 (0.46) | CDK2CCNE1JAK2JAK1JAK3 | |
| SCHEMBL3311179 | 0.90 | CDK2 (0.51) | CDK2CCNE1CDK1CCNKCDK12 | |
| SCHEMBL4408483 | 0.90 | CDK2 (0.47) | CDK2CCNE1CDK1CCNKCDK12 | |
| SCHEMBL3306129 | 0.90 | CDK2 (0.47) | CDK2CCNE1CDK1CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220068-B1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2220068-B1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8309718-B2 | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309718-B2 | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309718-B2 | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090318405-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318405-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318405-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009064835-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318405-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | CDK2 135/4885CCNE1 1514/4885CDK1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.